Zhuang Tong Author
Subjects of specialization
Affiliation
Oncogenic; KRAS; EGFR; Mutations
Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, China
Zhuang Tong Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, No.44 Xiaoheyan Road, Dadong District, Shenyang 110042, Liaoning Province, China |
Research Article Open Access
Author(s): David Graf Brohawn, Xiaofeng Mu, Zhuang Tong, Elizabeth Rao, Ye Wang and Xinmin Li*
Many modern therapies target oncogenic mutations identified in a patient’s biopsied tumor cells. The process of identifying these mutations can be costly, labor-intensive, and requires significant technical expertise. Biocartis’ Idylla system, a real time PCR-based machine, streamlines oncogenic DNA mutation testing, directly from formalin-fixed paraffin embedded tissue with only 2 minutes hands-on time The instrument reports the presence or absence of clinically-relevant oncogenic mutations in KRAS, EGFR, BRAF, and/or NRAS in ≤ 2.5 hours per sample.
In this study, we tested how quickly and accurately the Biocartis Idylla detect oncogenic KRAS and EGFR mutations previously identified in 46 formalin-fixed paraffin embedded human patient biopsy samples. The ... view moreĀ»